Arrowstreet Capital Limited Partnership Trims Stock Holdings in DaVita Inc. (NYSE:DVA)

Arrowstreet Capital Limited Partnership trimmed its stake in DaVita Inc. (NYSE:DVA - Free Report) by 30.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 162,520 shares of the company's stock after selling 71,850 shares during the period. Arrowstreet Capital Limited Partnership owned 0.20% of DaVita worth $24,305,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. increased its stake in shares of DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after purchasing an additional 92,014 shares in the last quarter. Amundi lifted its position in DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after purchasing an additional 240,126 shares during the last quarter. KBC Group NV increased its stake in DaVita by 0.8% during the fourth quarter. KBC Group NV now owns 316,155 shares of the company's stock worth $47,281,000 after acquiring an additional 2,636 shares during the last quarter. Nordea Investment Management AB raised its holdings in DaVita by 4.9% during the 4th quarter. Nordea Investment Management AB now owns 264,535 shares of the company's stock valued at $39,712,000 after buying an additional 12,339 shares during the period. Finally, FMR LLC lifted its holdings in shares of DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company's stock worth $29,082,000 after acquiring an additional 154,061 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Wall Street Analysts Forecast Growth

DVA has been the topic of a number of recent research reports. Barclays increased their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. Cowen reaffirmed a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on DaVita in a report on Friday, February 21st. Finally, StockNews.com lowered shares of DaVita from a "buy" rating to a "hold" rating in a research note on Wednesday, April 2nd. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $166.33.

DaVita Stock Performance

Shares of DVA stock traded down $2.98 during mid-day trading on Tuesday, hitting $143.63. The stock had a trading volume of 904,702 shares, compared to its average volume of 816,972. The firm has a market cap of $11.49 billion, a PE ratio of 13.37, a PEG ratio of 1.07 and a beta of 1.04. The company's 50-day simple moving average is $153.98 and its 200-day simple moving average is $156.84. DaVita Inc. has a fifty-two week low of $125.64 and a fifty-two week high of $179.60. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping analysts' consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Sell-side analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.